Catalent Amps Up Contract Biological Manufacturing Capacity Plans to $200 million, an Industrial Info Market Brief
Catalent Amps Up Contract Biological Manufacturing Capacity Plans to $200 million, an Industrial Info Market Brief
Attachment: Catalent
On the heels of an already ambitious $100 million expansion plan, Catalent Incorporated has upped the ante by another $100 million. Catalent will invest $100 million in its bulk biological site in Madison, Wisconsin, with the other $100 million going to the Bloomington, Indiana, site. The company bought the 875,000-square-foot Blooomington site last year from Cook Pharmica for $950 million to further expand into biological contract manufacturing.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Novo Nordisk Spends $11 Billion to Make More Weight Loss Drugs
- EU Adds New COVID-19 Manufacturing Capacity
- Pfizer-BioNTech, Moderna and Johnson & Johnson Ramp Up COVID-19 Vaccines fo...
- Catalent Preps Early for COVID-19 Vaccine Production, an Industrial Info Ma...
- ISPE Names the 2017 Pharmaceutical Facility of the Year Category Awards